DE60213237D1 - Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii - Google Patents

Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii

Info

Publication number
DE60213237D1
DE60213237D1 DE60213237T DE60213237T DE60213237D1 DE 60213237 D1 DE60213237 D1 DE 60213237D1 DE 60213237 T DE60213237 T DE 60213237T DE 60213237 T DE60213237 T DE 60213237T DE 60213237 D1 DE60213237 D1 DE 60213237D1
Authority
DE
Germany
Prior art keywords
biotin
patients
treatment
diabetes mellitus
acetylcarnitine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213237T
Other languages
English (en)
Other versions
DE60213237T2 (de
Inventor
Sigma Calvani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of DE60213237D1 publication Critical patent/DE60213237D1/de
Publication of DE60213237T2 publication Critical patent/DE60213237T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60213237T 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii Expired - Lifetime DE60213237T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001RM000294A ITRM20010294A1 (it) 2001-05-29 2001-05-29 Uso della acetil l-carnetina in associazione con la biotina per il trattamento di pazienti affetti da diabete mellito di tipo ii insulino re
ITRM20010029 2001-05-29
PCT/IT2002/000338 WO2002096410A1 (en) 2001-05-29 2002-05-24 Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus

Publications (2)

Publication Number Publication Date
DE60213237D1 true DE60213237D1 (de) 2006-08-31
DE60213237T2 DE60213237T2 (de) 2007-08-02

Family

ID=11455558

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213237T Expired - Lifetime DE60213237T2 (de) 2001-05-29 2002-05-24 Verwendung von l-acetylcarnitin in kombination mit biotin zur behandlung von patienten mit insulinresistentem diabetes mellitus typ ii

Country Status (18)

Country Link
US (2) US20040142879A1 (de)
EP (1) EP1399142B1 (de)
JP (1) JP4381685B2 (de)
KR (1) KR20040010666A (de)
AT (1) ATE333274T1 (de)
CA (1) CA2448244C (de)
CY (1) CY1105403T1 (de)
CZ (1) CZ297743B6 (de)
DE (1) DE60213237T2 (de)
DK (1) DK1399142T3 (de)
ES (1) ES2268053T3 (de)
HU (1) HUP0400060A2 (de)
IT (1) ITRM20010294A1 (de)
MX (1) MXPA03010921A (de)
PL (1) PL207522B1 (de)
PT (1) PT1399142E (de)
SK (1) SK287832B6 (de)
WO (1) WO2002096410A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE339445T1 (de) * 2000-12-15 2006-10-15 Sigma Tau Ind Farmaceuti Verwendung von l-carnitin als stabilitsator für proteine
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
US8569366B2 (en) * 2005-04-26 2013-10-29 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes
EP1832295A1 (de) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
SG193655A1 (en) * 2007-03-21 2013-10-30 Sigma Tau Ind Farmaceuti Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance
GB201304112D0 (en) * 2013-03-07 2013-04-24 Univ Nottingham Modulation of energy expenditure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
US6020139A (en) * 1995-04-25 2000-02-01 Oridigm Corporation S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes

Also Published As

Publication number Publication date
CY1105403T1 (el) 2010-04-28
PL207522B1 (pl) 2010-12-31
JP4381685B2 (ja) 2009-12-09
CZ20033221A3 (cs) 2004-06-16
EP1399142B1 (de) 2006-07-19
DE60213237T2 (de) 2007-08-02
PT1399142E (pt) 2006-10-31
SK15852003A3 (sk) 2004-04-06
ATE333274T1 (de) 2006-08-15
EP1399142A1 (de) 2004-03-24
CZ297743B6 (cs) 2007-03-21
HUP0400060A2 (hu) 2004-04-28
CA2448244C (en) 2010-11-02
ES2268053T3 (es) 2007-03-16
DK1399142T3 (da) 2006-10-30
ITRM20010294A0 (it) 2001-05-29
JP2004532866A (ja) 2004-10-28
ITRM20010294A1 (it) 2002-11-29
US20040142879A1 (en) 2004-07-22
CA2448244A1 (en) 2002-12-05
SK287832B6 (sk) 2011-11-04
KR20040010666A (ko) 2004-01-31
PL367630A1 (en) 2005-03-07
US8053472B2 (en) 2011-11-08
US20080269307A1 (en) 2008-10-30
WO2002096410A1 (en) 2002-12-05
MXPA03010921A (es) 2004-02-27

Similar Documents

Publication Publication Date Title
DE602005020269D1 (de) Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
RS93604A (en) Substituted phenylacetamides and their use as glucokinase activators
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
DE69719931T2 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
DE502004006619D1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
CY1105403T1 (el) Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60118769D1 (de) Verwendung von langem pentraxin ptx3 zur behanlung von durch geänderte aktivität des fgf-2 wachstumsfaktors hervorgerufene krankheiten
DE60305279D1 (de) Verwendung von Methyltestosteron zur Behandlung von menschlichen Papillomavirus Infektionen
ATE284703T1 (de) Kristallmodifikation eines cyclischen depsipeptids mit besserer wirksamkeit
ATE354361T1 (de) Neue verwendung von prodigiosin zur behandlung von diabetes mellitus
ATE382054T1 (de) Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE50207110D1 (de) Kombinationspräparat zur behandlung des diabetes mellitus
ATE454897T1 (de) Verwendung von winterbohnenkraut (satureja montana) oder seinen extrakten zur herstellung von medikamenten zur behandlung von vorzeitiger ejakulation
DE60216090D1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
DE60120985D1 (de) Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens
DE60306344D1 (de) Behandlung von typ i diabetes mellitus mit wachstumshormonantagonisten
DE60222662D1 (de) Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post-chirurgischen schmerzbehandlung
DE50000676D1 (de) Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition